Maura N. Dickler, MD, Memorial Sloan Kettering Cancer Center, discusses next steps with abemaciclib following the results of the single-arm MONARCH 1 trial, which examined the efficacy of the CDK4/6 inhibitor in heavily pretreated patients with refractory, hormone-receptor–positive, HER2-negative advanced breast cancer.

свернуть